GT729
/ Grit Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 29, 2025
A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Grit Biotechnology
New P1 trial • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology
1 to 1
Of
1
Go to page
1